^
BIOMARKER:

HR negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
HR negative
HER2 Positive Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
J Chemother - 6 days
HR negative
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
Cancers (Basel) - 2 weeks
HR negative
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HR negative
HER2 Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: C2 – Inclusion Criteria
HR negative
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
HR negative
HER2 Negative Breast Cancer
olaparib
Sensitive: C3 – Early Trials
HR negative
HER2 Positive Breast Cancer
tegafur/uracil
Sensitive: C3 – Early Trials
HR negative
Hormone Receptor Negative Breast Cancer
TCHP
Sensitive: C3 – Early Trials
HR negative
HER2 Positive Breast Cancer
pertuzumab
Sensitive: C3 – Early Trials
HR negative
HER2 Negative Breast Cancer
AMG 479
Sensitive: C3 – Early Trials
HR negative
HER2 Positive Breast Cancer
trastuzumab + paclitaxel + pertuzumab
Sensitive: C3 – Early Trials
HR negative
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: C3 – Early Trials
HR negative
HER2 Positive Breast Cancer
pembrolizumab + pertuzumab + Trazimera (trastuzumab biosimilar)
Sensitive: C3 – Early Trials